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ABSTRACT 
ENVIRONMENTAL CHEMICALS POTENTIALLY INTERFERE WITH THYROID 
HORMONE ACTION IN HUMAN TERM PLACENTA 
 
FEBRUARY 2012 
 
KATHERINE GEROMINI, B.S., UNIVERSITY OF MASSACHUSETTS AMHERST 
 
M.S., UNIVERSITY OF MASSACHUSETTS AMHERST 
 
Directed by: Professor R. Thomas Zoeller 
 
Thyroid hormone is essential for normal brain development and recognition 
of this has led to universal screening of newborns for thyroid function to ensure that 
circulating levels of thyroid hormone are within a range known to be supportive of 
normal growth and mental development.  Environmental chemicals that interfere 
with thyroid function are known to inhibit normal growth and mental development.  
Work from our lab and from labs internationally demonstrates in animal systems 
that some industrial chemicals such as PCBs, PBDEs, and others may interact with 
the thyroid hormone receptor(s) in ways that are not predicted by changes in serum 
thyroid hormone levels.  Our work demonstrates that the enzyme CYP1A1 must 
metabolize some individual PCB congeners before they can interact with the thyroid 
receptor.  In animals, this requirement appears to be manifested in part by a strong 
correlation between CYP1A1 and TH target gene expression.  Here we present that 
this pattern extends to humans by demonstrating a correlation between increased 
CYP1A1 mRNA and an abundance of thyroid hormone responsive gene mRNA. 
 vi
TABLE OF CONTENTS 
 Page 
 
ACKNOWLEDGMENTS ......................................................................................................................... iv 
ABSTRACT ................................................................................................................................................. v 
TABLE OF CONTENTS .......................................................................................................................... vi 
LIST OF TABLES .................................................................................................................................... vii 
LIST OF FIGURES ................................................................................................................................ viii 
CHAPTER 
1. INTRODUCTION .................................................................................................................................. 1 
Thyroid Hormone Action and Disruption ....................................................................... 1 
PCBs Disrupt Thyroid Hormone Action in a Way That Is Inconsistent 
with Hypothyroidism................................................................................................ 2 
Maternal Thyroid Hormone and Role of the Placenta................................................ 6 
Summary ...................................................................................................................................... 8 
2. METHODS .............................................................................................................................................. 9 
Human Participation ............................................................................................................... 9 
Thyroid Function Analysis .................................................................................................... 9 
Placental Samples ..................................................................................................................... 9 
RNA Isolation and Treatment ............................................................................................10 
Quantitative RT-PCR .............................................................................................................11 
Statistical Analysis .................................................................................................................12 
3. RESULTS ..............................................................................................................................................13 
CYP1A1 mRNA Expression Is Correlated with the Expression of 
mRNAs of TH Responsive Genes ........................................................................13 
CYP1A1 mRNA Expression Is Not Correlated with Measures of 
Maternal T4 or Cord Blood T4 Levels ................................................................16 
TH Responsive Gene Expression in the Placenta Is Not Predicted by 
Maternal Serum T4 Levels .....................................................................................18 
CYP1A1 mRNA Expression Is Not Affected by the Smoking of Mothers............19 
4. DISCUSSION ........................................................................................................................................20 
CYP1A1 and Thyroid Responsive Gene Induction .....................................................20 
T4 Levels and Gene Induction ............................................................................................21 
Smoking During Pregnancy ................................................................................................22 
5. CONCLUSIONS ...................................................................................................................................23 
REFERENCES ..........................................................................................................................................24 
 
 vii
LIST OF TABLES 
Table Page 
 
1. Quantitative RT-PCR Primers. .................................................................................................. 11 
 
 viii
LIST OF FIGURES 
Figure Page 
 
1. Representative examples of PCB congeners used in the Gauger et al. 2007 
experiment. .............................................................................................................................. 3 
2. Proposed model for thyroid receptor activation by CYP1A1 metabolism of 
non-coplanar PCBs. ............................................................................................................... 4 
3. Cross-sectional diagram of the human term placenta. ................................................... 10 
4. Correlation between CYP1A1 and PL relative mRNA levels. ........................................ 13 
5. Correlation between CYP1A1 and GH-V relative mRNA levels. ................................... 14 
6. Correlation between PL and GH-V relative mRNA levels. .............................................. 15 
7. CYP1A1 relative mRNA levels compared to measures of T4. ........................................ 16 
8. PL and GH-V relative mRNA levels compared to measures of maternal T4. ........... 18 
9. CYP1A1 mRNA in smoking versus and nonsmoking mothers. .................................... 19 
 
 1 
CHAPTER 1 
INTRODUCTION 
Thyroid Hormone Action and Disruption 
Thyroid hormone (TH) is necessary for the proper functioning of the human 
body, but temporally and spatially specific actions of thyroid hormones play 
important roles in development. It is widely recognized that TH is necessary for 
proper fetal neurodevelopment, with TH deficiencies being linked to lower cognitive 
function. When hypothyroidism is untreated at birth, serious mental deficiencies 
quickly develop, and recognition of this has led to a screening of all newborns for 
thyroid function.[1] 
The effects of thyroid hormone within the adult human body and the 
developing fetus are controlled by a complex and multifaceted system. Serum levels 
regulate the production of the thyroid hormones triiodothyronine (T3) and 
thyroxine (T4). Transporters control the movement of these hormones into specific 
tissues, where they interact with the thyroid receptor (TR), which binds to the 
thyroid response element (TRE) and induces or represses gene transcription. 
Thyroxine-binding globulin binds T4 in serum, creating a reservoir of hormone in 
circulation. The amount of deiodinases (e.g. D2, D3) also plays a role in the level of 
thyroid hormones in different tissues, activating TH by converting T4 to the thyroid 
receptor activator T3, or deactivating TH by converting it to an unusable form. The 
complexity of thyroid hormone signaling, as well as the mechanisms of chemical 
disruption are fully reviewed by Zoeller (2010)[2]. Because thyroid hormone 
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signaling is so complex, it should be expected then that any chemical disrupting 
some point in this system would have a complex pattern of effects. 
One such group of chemicals that have been linked to altered levels of TH is 
polychlorinated biphenyls (PCBs). PCBs could affect TH signaling by reducing serum 
TH levels, interfering with the TR, or both. 
PCBs Disrupt Thyroid Hormone Action in a Way That Is Inconsistent with 
Hypothyroidism 
PCBs are persistent environmental pollutants. Once used in industry for a 
variety of purposes, production of these chemicals was banned in the 1970s. Despite 
this, they remain ubiquitous, unavoidable contaminants in the environment and in 
the human population[3]. PCBs and their hydroxylated metabolites (OH-PCBs) are 
present in cord blood in concentrations that are predicted by maternal exposure[4], 
indicating the fetus is also exposed to these chemicals during development. 
PCBs are composed of two linked benzene rings with varying degrees and 
placement of chlorination. Because of the differences in structures among these 
individual congeners, they can have different biological effects[5]. Study of these 
effects is complicated because commercial mixtures of PCBs are composed of 
different congeners at varying ratios of concentration. Further, the ratios found in 
the environment and in the human body are different from those of commercial 
mixtures. Little research has focused on how mixtures of these chemicals are 
interacting in the human body[6, 7].  
In different mixtures, PCB congeners could interact to have different effects. 
Congeners with similar actions could have additive effects while congeners with 
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different actions may together form new patterns of disruption. Gauger et al. (2007) 
have shown that mixtures of PCBs can cause an increase in TH responsive genes, but 
when individual congeners (shown in Figure 1) are tested alone this effect is not 
seen[8]. What chemical properties then of different PCB congeners could interact to 
create this? 
 
Figure 1. Representative examples of PCB congeners used in the Gauger et al. 
2007 experiment. (A) Non-ortho PCB congeners, “dioxin-like”: 3,3’,4,4’-
tetrachlorobiphenyl (PCB 77) and 3,3’,4,4’,5-pentachlorobiphenyl (PCB 126). 
(B) Mono-ortho PCB congeners: 2,3,3’,4,4’-pentachlorobiphenyl (PCB 105) and 
2,3’,4,4’,5-pentachlorobiphenyl (PCB 118). (C) Di-ortho PCB congeners: 
2,2’,3,4,4’,5’-hexachlorobiphenyl (PCB 138) and 2,2’,4,4’,5,5’-
hexachlorobiphenyl (PCB 153).[8] 
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Congeners can be coplanar or non-coplanar, depending upon the placement 
of chlorine. The coplanar PCBs, such as PCB 126, have dioxin-like effects: that is, 
they activate the arylhydrocarbon receptor (AhR) and induce transcription of the 
gene encoding the phase-I metabolic enzyme cytochrome P4501A1 (CYP1A1)[6]. 
The AhR is expressed in many fetal tissues as well as being highly expressed 
in the human placenta. Areas of higher expression in the fetus include the lung and 
liver, while the brain shows lower expression levels.[9]  
Non-coplanar PCBs are not dioxin-like, but have other biological actions[6].  
Results of dual-luciferase assays by Gauger et al. (2007) show that CYP1A1 
induction and activity is necessary for specific non-coplanar, mono-ortho-
substituted, PCBs 105 and 118 to drive thyroid receptor (TR) activation[8]. 
 
Figure 2. Proposed model for thyroid receptor activation by CYP1A1 
metabolism of non-coplanar PCBs. The AhR is activated by coplanar PCBs or 
other chemicals, inducing the expression of CYP1A1. The CYP1A1 enzyme 
metabolizes non-coplanar, mono-ortho-substituted PCBs into their 4-hydroxy 
metabolites. These hydroxylated forms interact with the thyroid receptor and 
cause the transcription or regulation of thyroid hormone responsive 
genes.[10] 
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The following model has been proposed: that CYP1A1 metabolizes non-
coplanar, mono-ortho-substituted PCBs, such as 105 and 118, into their 4-hydroxy 
metabolite forms [e.g. 4-hydroxy-2,3,3′,4′,5-pentachlorobiphenyl (4-OH-
PCB107)[11]] and that these metabolites, which have similar chemical structure to 
thyroid hormone, interact with the TR[12](Figure 2). This two-step process, in 
which CYP1A1 mRNA expression is positively correlated with the expression of 
genes regulated by thyroid hormone, provides us with a prediction to test this 
action in other systems. 
To test this hypothesis in vivo Giera et al. (2011) treated timed-pregnant rats 
with various PCB mixtures and observed the gene expression in tissues of the pups 
(i.e. liver, heart, pituitary). PCBs 105 and 118 induced the thyroid hormone 
responsive genes Spot 14 and malic enzyme in liver, where the AhR is highly 
expressed, only in the presence of the dioxin-like PCB 126. This addition of PCB 126 
also corresponds to an increase of CYP1A1 mRNA, consistent with our hypothesis 
that CYP1A1 is necessary to create metabolites which in turn cause induction of TH 
responsive genes.  
PCB exposure displayed different effects in different tissues. Mixtures 
containing PCB 126 were able to cause an increase in CYP1A1 mRNA to a lesser 
extent in pituitary, and yet there was no corresponding decrease in the thyroid 
hormone inhibited gene, TSHβ, mRNA. Despite the pups given mixtures containing 
PCB 126 still showing the decrease in T3 and T4, the tissue mRNA response was not 
consistent with the positive control for hypothyroidism. It was concluded that, 
within these tissues, CYP1A1 was not highly expressed enough to metabolize PCB 
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congeners and cause a change in TH signaling.  This clearly underlines that a 
mixture of chemicals, as well as having unanticipated interactions, can have 
paradoxical tissue and serum specific effects[10]. 
Maternal Thyroid Hormone and Role of the Placenta 
The next question this raises is whether this metabolism observed in vitro 
and in vivo can create metabolites in humans that can interact with the TR and cause 
gene expression changes. Placenta was an obvious choice for examination; it is 
easily collected after birth from live healthy donors and it plays an important role in 
thyroid hormone delivery to the fetus[13]. 
Until relatively recently, it was believed that the placenta blocked the 
transfer of thyroid hormone from the mother to the fetus. Deiodinases D2 and D3, 
enzymes that inactivate thyroid hormone, are indeed present at high levels in the in 
the placenta[14]. However, the fact that permanent developmental effects of 
congenital hypothyroidism can be almost completely prevented by immediate T4 
treatment after birth indicated that the developing fetus is protected by the mothers 
T4 production. By treating pregnant rats with the antithyroid drug methimazole and 
then rescuing with T4 injections, Calvo et al. were able to demonstrate in 1990 the 
necessity of maternal T4 to the protection of pup brains from hypothyroidism[15]. 
Vulsma et al. proved the same protective effect in humans by demonstrating that 
newborns completely lacking the genetic ability to synthesis T4 have detectable T4 in 
cord blood at delivery, and develop the profile of hypothyroidism only after birth 
[16]. 
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Because the thyroid hormone axis of the mother is linked to thyroid hormone 
levels in the fetus and to its development, chemicals that disrupt TH signaling of the 
mother affect the fetus as well. Not only is placenta one of the few tissues readily 
available from healthy human donors, but endpoints observed in this tissue have 
implications for both mother and child. 
The TH responsive genes measured in this study were placental lactogen 
(PL) and placental growth hormone (GH-V). In vitro studies have shown the TR to 
interact with a thyroid response element of these genes[17]. Addition of T3, the 
active form of TH, is observed in cell line studies to increase the transcription of 
PL[18-20] and GH-V[18]. If the expression of these genes correlates with expression 
of CYP1A1 mRNA, this is evidence that environmental chemical metabolites are 
affecting thyroid responsive gene expression. 
By collaboration with Dr. Larissa Takser (Sherbrooke University Hospital, 
Quebec, Canada) we were provided with an opportunity to test this model in 
humans. Dr. Takser provided us with a large sample of human placentas in order to 
examine gene expression in this tissue. 
These placentas were collected as part of an epidemiological study (named 
GESTE) that recruited women in 2007 living in the Eastern Townships region of 
Quebec, Canada during pregnancy. GESTE will follow these mother-infant pairs for 
at least four years to assess the effects and magnitude of endocrine disruption on 
maternal health and child development. 
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Summary 
Through our interdisciplinary collaboration, this research has the potential 
to increase our understanding of the mechanisms of this example of xenobiotic 
metabolism and eventually combine it with developmental endpoints. Being able to 
assess the CYP1A1 and TH responsive gene mRNA levels on a large sample of human 
placentas provides us with a unique and exciting opportunity to determine if the 
proposed model of metabolism extends to humans. 
We hypothesized that expression of CYP1A1 mRNA is positively correlated 
with the abundance of mRNAs coding for TR genes in the human term placenta. This 
would be consistent with AhR driven metabolism of certain chemicals to forms that 
interact with the TR. 
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CHAPTER 2 
METHODS 
Human Participation 
Recruitment and sample collection took place in 2007 at Étienne-Lebel 
Clinical Research (CRC) Center of the Sherbrooke University Hospital (CHUS) 
(Quebec, Canada). The Human Research Ethics Committee of CHUS approved the 
study protocol. Four hundred pregnant women were recruited for this study at their 
first physician visit. Each participant gave informed consent. All women were at or 
over the age of 18, less than twenty weeks pregnant, and had no known thyroid 
disease. 
Thyroid Function Analysis 
TH levels were measured by the Takser lab at Sherbrooke University. Serum 
free T4 (fT4) and total T4 were assessed in the mothers at recruitment (<20 weeks of 
pregnancy) and at delivery, as well as in cord blood at delivery. fT4 was determined 
by the  electrochemiluminescent immunoassay system ADVIA Centaur (Bayer) and 
total T4 by the Coat-A-Count radioimmunoassay (DPC Inc., Los Angeles, CA) at CHUS.  
Placental Samples 
Placentas were collected immediately upon delivery. Two placental lobes (i.e. 
cotyledons), morphological units of the placenta, were sampled from the center of 
the maternal side of each placenta (Figure 3).  Samples were immediately stored at -
80°C. Of these samples, one cotyledon was cut in half on ice and sent, stored in dry 
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ice, to our facility at the University of Massachusetts Amherst. 172 placental samples 
were received for use in this study. 
 
Figure 3.  Cross-sectional diagram of the human term placenta. (A) Highlights 
a cotyledon. Two such units were sampled during the course of this 
experiment. This sample contains largely maternally derived tissue, however 
some fetal tissue is also present.[21] 
RNA Isolation and DNase Treatment 
For each sample received, a piece of frozen placental tissue approximately 
300mg in weight was disrupted and homogenized with a Bullet Blender (Next 
Advance Inc., Averill Park, NY). Total RNA was isolated using TRIzol Reagent 
(Invitrogen Corporation, Carlsbad, CA), according to the manufacturer’s 
instructions. RNA was dissolved in DEPC treated water. Concentration of RNA was 
determined with a NanoDrop 1000 spectrophotometer (Thermo Scientific, 
Wilmington, DE). 
A 
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A subset of samples was tested for the presence of genomic DNA. With 
contamination of genomic DNA in the samples confirmed, all RNA samples were 
treated with DNase using the Applied Biosystems TURBO DNA-free procedure 
(Applied Biosystems, Inc., Foster City, CA). Concentration of treated RNA was again 
determined with the NanoDrop 1000. 
Quantitative RT-PCR 
One microgram of RNA from each sample was reverse transcribed using the 
Applied Biosystems High Capacity cDNA Reverse Transcription Kit by the 
manufacturer’s instructions.  
Each quantitative PCR reaction was 10μL in volume and was comprised of 
300nM forward and reverse primers each of the target gene (Table 1), nuclease free 
water, 5μL FastStart Universal SYBR Green Master (ROX) (Roche Diagnostics Corp., 
Indianapolis, IN) and cDNA. Because of the low abundance of CYP1A1 transcripts in 
placenta, it was necessary to use 4μg cDNA to obtain a significant signal in CYP1A1 
PCR reactions. For all other reactions, 1μg cDNA was used. 
Table 1. Quantitative RT-PCR Primers. 
Gene Forward Primer (5’3’) Reverse Primer (5’3’) 
CYP1A1 GCTCAGCTCAGTACCTCAGCCAC GGTCTTGAGGCCCTGATTACCCAG 
PL[22] CATGACTCCCAGACCTCCTTC TGCGGAGCAGCTCTAGATTCT 
GH-V[23] AGAACCCCCAGACCTCCCT TGCGGAGCAGCTCTAGGTTAG 
Β-actin[24] CCTGGCACCCAGCACAAT GGGCCGGACTCGTCATAC 
18S[25] ACACGGACAGGATTGACAGA GGACATCTAAGGGCATCACAG 
 
Quantitative PCR was performed using the Strategene Mx3000P real-time 
PCR machine (Agilent Technologies, Inc., Santa Clara, CA). Samples were run in 
duplicate for each gene. A calibrator pool was run in triplicate for each gene on each 
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plate. The following thermal profile was used for all runs: one cycle of 10 min at 
95°C; 40 cycles of 15 s at 95°C, 30 s at 60°C, and 15 s at 72°C; one cycle of 1 min at 
95°C, 30 s 55°C, and 30 s at 95°C. Melting-curve analysis was preformed to identify 
the creation of non-specific products, in which case all genes for the sample were 
rerun on a new plate. 
Relative mRNA levels were determined by the Pfaffl method[26]: the 
difference between cycle threshold number, as calculated by the Mx3000P software, 
for a target gene and the reference gene, β-actin, was compared between the sample 
and a calibrator pool to obtain a relative fold change value. 
Statistical Analysis 
Statistical analysis was carried out using Prism 4 (GraphPad Software, La 
Jolla, CA). Relative gene expression level data sets were tested for normality using 
the D’Agostino-Pearson omnibus K2 normality test and log transformed if necessary 
to be consistent with a Gaussian distribution. Pearson’s correlation test was used to 
compare the relative levels of CYP1A1 transcripts and thyroid hormone gene target 
transcripts. If a correlation was observed, the linear regression line was calculated. 
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CHAPTER 3 
RESULTS 
CYP1A1 mRNA Expression Is Correlated with the Expression of mRNAs of TH 
Responsive Genes 
 
Figure 4. Correlation between CYP1A1 and PL relative mRNA levels. PL and 
CYP1A1 show a weak but significant positive log-linear correlation [r2 = 
0.3924(df = 136), P < 0.0001]. Data were log transformed for statistical 
analysis. 
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Figure 5. Correlation between CYP1A1 and GH-V relative mRNA levels. GH-V 
and CYP1A1 show a weak but statistically significant positive log-linear 
correlation (r2 = 0.3565(df = 136), P < 0.0001). Data were log transformed for 
statistical analysis. 
 
Expression of CYP1A1 mRNA showed a correlation with the TH responsive 
genes PL and GH-V.  PL mRNA was correlated with CYP1A1 mRNA (Figure 4), r2 = 
0.3924(df = 136), P < 0.0001. GH-V mRNA was correlated with CYP1A1 mRNA 
(Figure 5), r2 = 0.3565(df = 136), P < 0.0001. mRNA expression data was log 
transformed to create a Gaussian distribution for statistical analysis. 
As a control, the fold change for the reference gene 18S was also compared to 
CYP1A1 (not shown). There was a significant but small correlation between CYP1A1 
and 18S relative fold change, r2 = 0.09425(df = 136), P = 0.0002 (log transformed 
data). 
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Figure 6. Correlation between PL and GH-V relative mRNA levels. PL and GH-V 
relative mRNA expression shows a high positive linear correlation (r2 = 
0.8827(df = 170), P < 0.0001). Data were log transformed for statistical 
analysis. 
 
PL and GH-V showed a very strong correlation with each other (Figure 6), r2 
= 0.8827(df = 170), P < 0.0001. This is expected, and consistent with other 
observations of parallel increase in transcription of these genes[27]. 
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CYP1A1 mRNA Expression Is Not Correlated with Measures of Maternal T4 or 
Cord Blood T4 Levels 
 
Figure 7. CYP1A1 relative mRNA levels compared to measures of T4. There was 
no correlation between CYP1A1 mRNA levels and maternal serum fT4 (A) [r2 = 
0.0005026(df = 110), P = 0.8145] or total T4 (B) [r2 = 0.03176(df = 112), P = 
0.0578] at delivery. There was no correlation between CYP1A1 mRNA levels 
and cord blood fT4 (C) [r2 = 0.006778(df = 118), P = 0.3714] or total T4 (D) [r2 
= 0.0001525(df = 118), P = 0.8935]. CYP1A1 data is log transformed for 
statistical analysis. 
 
The expression of CYP1A1 mRNA showed no correlation with measures of 
circulating free and total T4 levels, when data sets were examined as a group (Figure 
7). There was no correlation between CYP1A1 mRNA expression and maternal 
serum levels of fT4 [r2 = 0.0005026(df = 110), P = 0.8145] or total T4 [r2 = 
0.03176(df = 112), P = 0.0578]. Though the low P value for the correlation of total 
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maternal T4 and CYP1A1 mRNA could be interpreted as statistically significant, the 
r2 of nearly zero indicates that this is not a correlation of biological interest.  
To further analyze these findings, the data was broken into quintiles by T4 
levels (not shown). When examining maternal fT4 at delivery in this way, the fifth 
quintile, representing the group with the highest levels of fT4, shows a distinct 
positive correlation between relative levels of CYP1A1 mRNA and fT4 [r2 = 0.3527(df 
= 20), P = 0.0036]. This effect was not observed in any of the lower quintiles of fT4.  
When examining maternal serum total T4 at delivery by quintile, no 
correlations were observed between CYP1A1 relative mRNA levels and total T4. 
Neither were correlations observed between CYP1A1 relative mRNA levels and free 
or total T4 of cord blood, when divided into quintiles. 
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TH Responsive Gene Expression in the Placenta Is Not Predicted by Maternal 
Serum T4 Levels 
 
Figure 8. PL and GH-V relative mRNA levels compared to measures of maternal 
T4. PL shows no correlation with maternal fT4 at delivery (A) [r2 = 
0.0002523(df = 139), P = 0.8517] but a slight correlation with total T4 (B) [r2 = 
0.03927(df = 141) P = 0.0177].  Likewise, GH-V shows no correlation with fT4 
at delivery (C) [r2 = 0.00007266(df = 139), P = 0.9201] but a slight correlation 
with total T4 (D) [r2 = 0.04484(df = 141), P = 0.0111]. Relative fold induction 
data is log transformed for statistical analysis. 
 
The relative mRNA levels of the thyroid hormone responsive genes were 
compared to measures of maternal T4 (Figure 8). The expression of PL and GH-V 
mRNAs showed no correlation with the maternal level of fT4 at delivery. However, 
both genes (log transformed) showed a weak correlation with maternal serum total 
T4 at delivery. PL: r2 = 0.03927(df = 141), P = 0.0177 and GH-V: r2 = 0.04484(df = 
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142), P = 0.0111.  Such a low r2, however, indicates this effect is unlikely to be 
biologically significant. 
No correlations were found between thyroid hormone responsive gene 
expression and measures of T4 in cord blood (not shown). 
CYP1A1 mRNA Expression Is Not Affected by the Smoking of Mothers 
 
Figure 9. CYP1A1 mRNA in smoking versus and nonsmoking mothers. CYP1A1 
data (log transformed for statistical analysis) was grouped based on mothers’ 
reporting of smoking or not during pregnancy. The two groups were 
compared using the student’s t-test. There was no significant difference 
between the means of the two groups [t = 0.5995(df = 107), P = 0.5501]. 
 
 
No difference in placental CYP1A1 mRNA expression was found when 
mothers were grouped based on their reporting of smoking or not during pregnancy 
(Figure 9), t = 0.5995 (df = 107), P = 0.5501. This statistic, however, was reported 
for only a portion of participants, with only 14 participants reporting that they 
smoked during pregnancy. 
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CHAPTER 4 
DISCUSSION 
These findings lend support for the hypothesis that environmental chemicals 
can act as TH if they are metabolized by CYP1A1. This hypothesis has been tested in 
vitro and in an animal model, but the results reported here are the first indications 
that this mechanism extends into humans. 
CYP1A1 and Thyroid Responsive Gene Induction 
To see differences in TH action, we examined two genes known to be induced 
by T3 in placenta, PL and GH-V. The increase in mRNA levels of these genes was 
predicted by an increase in CYP1A1 mRNA. These data support the model that PCB 
metabolism by CYP1A1 can affect TH gene expression and capitulate observations in 
vitro and in vivo. This is consistent with the notion that CYP1A1 creates metabolites 
that act as TH agonists. 
As a negative control, we also examined a characterized housekeeping gene 
in placenta, 18S. This gene should not change expression as a response to thyroid 
hormone receptor activation. The correlation between CYP1A1 and 18S in placenta 
was comparatively smaller than the relationship between CYP1A1 and the target 
genes mRNA, supporting the conclusion that this response is specific to thyroid 
hormone receptor activation. 
In 20% of samples we were not able to obtain a qRT-PCR signal for CYP1A1. 
These samples were excluded from these comparisons; however, they represent an 
interesting subset of samples that should be investigated. It is likely the lack of 
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CYP1A1 signal represents no induction or a level of induction that is below our 
ability to detect. It would be interesting to examine if low exposure or genetic 
factors are the cause of the low CYP1A1 induction in these individuals. 
An additional interesting set of data to examine would be how CYP1A1 single-
nucleotide polymorphisms (SNPs) contribute to the observed correlation. CYP1A1 
SNPs have effects on gene expression[28] and enzyme activity[29, 30] and also are 
linked to an increased risk for a number of cancers[31-34]. 
T4 Levels and Gene Induction 
Studies have shown that T3 increases transcription of PL and GH-V in in vitro 
cell line systems. Though T3 levels account for much of the thyroid hormone action 
in tissue, T4 levels provide a more accurate overview of signaling in the body. Since 
T3 and T4 levels are indirectly related, we expected that we could predict serum T4 
levels from the PL and GH-V mRNA levels.  
We did not see any significant correlations between free or total T4 levels in 
maternal serum, or in cord blood, and the induction of TH responsive genes. This 
indicates a disconnection between hormone levels in serum and hormone action in 
tissue. The next step then is to examine TH levels in the tissue samples themselves 
to better understand how TH levels and gene expression are linked in placenta. 
We also observed that CYP1A1 mRNA levels did not predict T4 levels. We 
expected to see an effect on T4 related to this marker of PCB metabolism. In animal 
models, PCB exposure and CYP1A1 induction was linked to an increase in TR 
responsive genes mRNA[8, 10] that corresponded with a decrease in serum total T4. 
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Previous human studies, however, by the Takser lab found only a correlation 
between PCB exposure and T3 levels but not T4 levels[35]. Some studies now 
indicate that OH-PCB levels, but not total PCB levels, are correlated with declining 
fT4 levels[36]. 
These results indicate that T4 levels cannot predict gene expression in human 
placenta. Combining this data with measures of chemical exposure, as well as 
examining tissue TH levels, could provide a more accurate picture of chemical 
metabolism and its effects on the thyroid hormone axis. 
Smoking During Pregnancy 
To examine how behavior can affect exposure we looked to see if individuals 
who reported smoking had higher CYP1A1 mRNA levels, and therefore higher TH 
responsive gene mRNA levels. No difference in CYP1A1 mRNA levels was found 
between self-reported smoking and non-smoking during pregnancy. It is well 
established that smoking increases levels of CYP1A1 mRNA in human term-
placenta[37], as well as increases related enzymatic activity[38].  
A great amount of variability of this effect between individuals, however, has 
been reported and factors such as genetics and the extent and timing of smoking 
during pregnancy have been proposed to cause this[37]. Further, this statistic was 
reported for only 63% of participants, with only 14 individuals reporting to have 
smoked during their pregnancy. It is likely that for an enlightening analysis more 
data concerning this activity, such as examining chemical markers of smoking, is 
necessary than a self-reported binary. 
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CHAPTER 5 
CONCLUSIONS 
This test of the hypothesis that environmental chemicals can interfere with 
thyroid hormone signaling clearly supports the proposed model of PCB metabolism 
by CYP1A1. By observing the predicted effect of CYP1A1 on TH responsive genes, we 
demonstrate that, within the human population, exposure to environmental 
chemicals can cause a change in TH signaling.  
Further, we could not predict this effect by looking at serum hormone levels. 
This is not surprising, as this metabolism and disruption occurs on the level of the 
tissue, and previous studies indicate these tissue effects are not uniform. To what 
extent this affects the creation and circulation of TH remains to be seen. 
This research also underlines that the study of chemicals in isolation cannot 
provide the whole picture of the risk a chemical poses. An endocrine disruptor may 
only have an effect after a series of other factors have occurred. In this model, 
people with elevated levels of CYP1A1 for any reason (e.g. exposure to other dioxin-
like chemicals, smoking) could be at increased risk. Interaction with other chemicals 
must be considered. 
Recognition of the fact that proper TH signaling is essential for healthy 
human development has led to nearly universal screening of thyroid function at 
birth. Yet this realization has not penetrated other areas of concern, such as how 
signaling can be disrupted by the chemicals we put into our environment. Clearly we 
need to discover new endpoints for assessing the power of chemicals to interfere 
with thyroid hormone action. 
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